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Single genotypic variants of HIV-I, contained in a parental cytopathic HIV-I isolate, were isolated by molecular cloning 
and propagated in susceptible cells. Two such HIV-I clones, designated NIT-E and NIT-A, exhibited similar restriction 
endonuclease maps but strikingly different biological activities. Infection of T lymphocytes or monocytes by clone NIT-E 
was characterized by slow kinetics and lack of significant cytopathic effects, but high reverse transcriptase activity levels 
in culture supernatants of chronically-infected cells. Clone NIT-A, like the parental HIV-I isolate, exhibited fast kinetics 
of infection in T cells and monocytes and strong cytopathicity in these cells. Full characterization of the low-cytopathic 
virus in comparison to the structurally similar cytopathic clone may facilitate the elucidation of the molecular basis of 
HIV cytopathogenicity. 
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1. INTRODUCTION 
Human immunodeficiency virus type-I, the 
primary etiologic agent of the acquired im- 
munodeficiency syndrome [ 11, is believed to cause 
immunodeficiency in part by virtue of its 
cytopathic interaction with CD4-positive human T 
lymphocytes [2]. Recent reports have suggested 
that HIV-I isolates from individuals with mild or 
no symptoms of disease may be less 
cytopathogenic than viruses from AIDS patients 
[3-51. Attenuated cytotoxicity has been 
demonstrated for two different isolates of HIV-II 
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16,71, an HIV-I-related but different retrovirus 
associated with a form of immunodeficiency 
predominantly found in West Africa [8]. Here we 
describe an infectious molecular clone of HIV-I 
with low cytopathogenicity in human T cells and 
monocytes. The clone was isolated from a HIV-I- 
producer cell line CEM/HIV/NlT [9], which has 
previously been shown to contain multiple HIV-I 
genotypes [lo] and to produce a typical cytopathic 
virus [9,10]. Our results suggest that low- 
cytopathic and highly-cytopathic HIV-I clones can 
coexist in a single virus producing 
presumably, in one individual. 
culture and, 
2. MATERIALS AND METHODS 
2.1. Cells and viruses 
CDCpositive T cell lines used in these studies were obtained 
as follows: CEM cells [11] were the gift from L. Montagnier; 
the HIV-lysis resistant subclone of CEM, CRlO, was establish- 
ed in this laboratory [9]; HUT-102 B2 cells [12] were received 
from W. Green, and the human monocytoid cell line, U-937 
[13], was obtained from the American Type Culture Collection 
(ATCC, Rockville, MD). Suspension cell lines were maintained 
in RPMI-1640 medium (Gibco Laboratories, Grand Island, 
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NY) supplemented with 10% fetal bovine serum (FBS) and an- 
tibiotics. The NIT isolate of HIV [9,10] was propagated in 
CEM or CR10 cells; the single genotypic NIT virus clones (see 
below) were maintained in CEM cells. For infection studies, 
virus isolates were concentrated lOO-fold, tested for RT activity 
and infectivity, and stored at - 80°C until use. 
2.2. Molecular cloning of HIV proviruses 
Standard techniques described by Maniatis et al. [14] were 
employed. Briefly, genomic DNA from CEM/HIV/NlT cells 
[9,10] was prepared by a cesium chloride/guanidinium isothio- 
cyanate method. Cellular DNA was digested to completion with 
the .restriction enzyme XbaI, size fractionated on lo-40% 
sucrose density gradient, and cloned into the hJ1 phage vector 
(gift of J.I. Mullins). Recombinant clones were identified using 
“P-labeled HIV-I DNA probe NlG-G [lo], purified by plaque- 
hybridization. Proviral sequences were then subcloned in 
pUCl8, propagated and analyzed for biological activity by 
transfection and rescue of infectious progeny virus. 
2.3. Infectivity studies 
For suspension cell cultures, 1 x IO6 cells were adsorbed with 
the appropriate HIV clone (400000 cpm RT activity/l x lo6 
cells/I ml) for 1 h at 37°C. Cells were then washed once with 
phosphate-buffered saline (pH 7.4). resuspended in culture 
medium and cultured under standard conditions. At the 
designated time intervals, 1 ml aliquots were removed to deter- 
mine total cell count, viability, RT activity in culture superna- 
tant and HIV antigen expression in cells by the IF method. 
2.4. Analytical assays, chemicals, and radiochemicals 
HIV infection was monitored as described previously [9] by 
detecting the presence of HIV antigens in infected cells using the 
IF method and/or by measuring the level of RT in culture 
supernatants. Enzymes for recombinant DNA experiments were 
purchased from New England Biolabs, Inc. (Beverly, MA) and 
Bethesda Research Laboratories (Gaithersburg, MD) and 
FITC-conjugated anti-human IgG from Tago Im- 
munochemicals (Burlingame, CA). All radiochemicals were ob- 
tained from New England Nuclear Corp. (Boston, MA), and 
other chemicals were purchased from Sigma Chemical Co. (St. 
Louis, MO). 
3. RESULTS AND DISCUSSION 
3.1. Isolation of genetically polymorphic 
infectious molecular clones of HIV-I present 
in a single virus isolate 
HIV-I/NlT was isolated from peripheral blood 
lymphocytes of a patient with lymphadenopathy as 
described [151. Virus was propagated in CEM cells 
or in chronically-infected CR-10 cells [9] and 
characterized as a T cell-tropic, highly-cytopathic 
retrovirus closely resembling prototypic HIV-I 
strains [9,10,15]. As shown for several other HIV-I 
and HIV-II isolates [6,16,17], HIV-I/NlT virus 
was found to contain multiple virus genotypes 
[lo]. A recombinant DNA phage library prepared 
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from HIV-I/NlT-producer cells yielded 21 HIT-I 
positive clones, 6 of which were analyzed and five 
of them were found to contain a full-length pro- 
viral DNA. Five of the 6 clones could be 
distinguished by restriction endonuclease map- 
ping, and all but one were biologically active. 
Thus, like the previously described HIV-I/IIIB 
and HIV-2s~ isolates [6,17], HIV-I/NIT virus con- 
tains multiple different genotypes that are capable 
of producing infectious progeny virus. Fig. 1 shows 
restriction endonuclease maps of two such NIT 
virus clones, NlT-A and NIT-E, described in this 
communication. Similarity in restriction patterns, 
in particular in the 5 ‘-half of NIT-A and NlT-E 
genomes, suggests close genetic relationship be- 
tween these variants, as previously reported for 
other multiple proviral DNA clones from in- 
dividual patients [ 161. 
3.2. Presence of low-cytopathic HIV-I/N1 T clone 
among highly cytopathic variants in the same 
producer cell line 
Comparative functional analysis of the different 
NlT provirus DNA clones revealed that 4 of 5 
clones, termed NlT-A, -B, -C and -D, produced 
progeny viruses whose biological properties were 
similar to the parental isolate; namely, they ex- 
hibited rapid kinetics of infection and induced 
massive cell fusion and cytolysis. An example of 
such a study using NlT-A clone and CEM cells is 
shown in fig.2A. In contrast, an equivalent dose of 
the 5th clone, termed NlT-E, did not induce cell 
aggregation or any substantial cell lysis and fusion 
(fig.2B). An infection kinetics study, using T lym- 
phoid cell lines CEM and HUT-102, and a 
monocytic cell line U-937, confirmed that NlT-E 
exhibited significantly attenuated cytopathicity as 
compared to NlT-A (table 1). The limited 
cytopathicity of NlT-E was not due to low infec- 
tivity of this variant, because all 3 cell lines were 
comparably susceptible to infection with both 
variant viruses, as shown by the virus-specific IF 
assay and detection of RT in culture supernatants. 
However, only E virus-infected cells survived 
primary infection and remained chronically in- 
fected (table 1). Noncytopathic infection of 
HUT-102 cells with NIT-E virus is particularly 
striking, because HTLV-I-carrying T cell lines are 
known to be exquisitely susceptible to HIV- 
induced lysis and fusion [ 181. 
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Fig. 1. Restriction endonuclease map of cytopathic and low-cytopathic molecular clones of HIV-I. All clones contain a full-length HIV- 
1 provirus (upper thin line) flanked by cellular sequences (lower bold line). Asterisks denote sites absent in NIT-A virus. Restriction 
enzyme cleavage sites: Ba, BarnHI; B, Bg/II; E, EcoRI; H, HindIII; K, &WI; Ps, PsfI; P, PvuII; S, SacI; Sa, So/I; Sm, SmaI; Xb, 
XbaI; x, x/201. 
One of the advantageous consequences of the at- 
tenuated cytopathic property of the NlT-E virus is 
that cells that normally succumb to the cytopathic 
effects of HIV, such as the 3 cell targets listed in 
table 1, can become chronic carriers and producers 
of the virus (table 1, fig.3). Hence, potential ef- 
fects of chronic HIV infection on cellular gene ex- 
pression [ 191 and cell function [20] can be 
evaluated without the background of cytolysis. It 
is also of interest that CEM cells chronically in- 
fected with NlT-E replicated virus to much higher 
levels (as judged by the supernatant RT levels) than 
the respective cultures of NlT-A or parental NlT 
virus (fig.3). This result suggests that massive virus 
replication is not, by itself, sufficient for cell kill- 
ing by HIV. 
Fig.2. Effect of a cytopathic and low-cytopathic HIV-I clone on morphology of infected cells. CEM cells were exposed to (A) NIT-A 
or (B) NIT-E variant of HIV-I/NIT (400000 cpm of viral RT activity/l x lo6 cells per ml) and observed for cell aggregation, 
formation of multinucleated giant cells, and cell degeneration 3 days after infection. 
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Table 1 
Infectivity and cytopathogenicity of NIT-E and NIT-A clones tested in human T-lymphoid and monocytoid cell lines 
Cell Virus 
line clone 
1 week 
V= HIV-Ag RT 
HUT-102 NIT-E 81.2 <I 5.9 
HUT-102 NlT-A 38 91.7 8.0 
u-937 NIT-E 75 <1 3.4 
u-937 NlT-A 22.2 63.3 3.2 
CEMb NIT-E 99 <1 3.3 
CEMb NIT-A 36 66.3 7.8 
a V, viability 
b Sample times for CEM cells were 1, 2 and 6 weeks 
Time after primary infection 
3 weeks 
V HIV-Ag RT 
97.5 90.2 4.7 
0 N.D. N.D. 
96.1 <l 1.7 
22.2 76.4 2.1 
84.3 81 214.8 
12.5 71.8 32.1 
7 weeks 
V HIV-Ag RT 
N.D. N.D. N.D. 
95 84.9 21.4 
0 N.D. N.D. 
90.8 93 702.3 
0 N.D. N.D. 
Cells were exposed to NlT-A or NIT-E virus and tested at the designated times after infection as described in section 2. Cell viability, 
determined by trypan blue exclusion method, is expressed here as % living cells; HIV-Ag represents % cells staining positive for HIV-I 
antigens by an IF assay; RT represents viral reverse transcriptase activity in culture supernatant, expressed as cpm x 10m3. Note that 
cells which are not viable by trypan blue exclusion criterion can still stain positive for HIV antigens. N.D., not done 
The basis for the observed low cytopathicity of 
NlT-E virus is unclear. One possibility is a defect 
at the level of virus entry, as suggested for a non- 
cytopathic HIV-11s~ [6]. Such a defect would imply 
that only a small proportion of virus preparation 
(i.e., nondefective particles) would be able to enter 
cells at any given time. Higher multiplicity of in- 
fection of an input virus should then correlate with 
increased cytopathicity, but that was not the case 
with HIV-11s~ [6] or NlT-E described here (not 
shown). Alternatively, the defect could be at the 
level of virus expression during some stage after 
virion penetration. This view is supported by the 
6- A-A NIT-A 
I, 
O-O NIT-E 
O---o HIV/NIT 
x 
2 
\ 
5 
0 
g 
4 
L 
8 10 12 14 16 18 20 
TIME IN CULTURE (WEEKS) 
Fig.3. Replication of HIV/NlT variants in chronically infected 
cells. NIT-E virus was propagated in CEM cells; the highly 
cytopathic NIT-A and parental NIT viruses were propagated in 
lysis-resistant CR-10 cells [9]. 
fact that only a small proportion of cells expressed 
viral antigens until l-2 weeks after infection (table 
l), whereas viral transcripts could be detected 4 
days postinfection (not shown). Delayed expres- 
sion of viral functions or viral latency have been 
proposed as one of the mechanisms responsible for 
HIV-I persistence in resting T lymphocytes [21,22]. 
Antigenic stimulation of such cells results in ac- 
celerated expression or reactivation of the latent 
viral genome [22]. Analysis of NIT-E viral gene ex- 
pression during early stages of infection could 
allow us to distinguish between these two 
possibilities. 
4. CONCLUSIONS AND IMPLICATIONS 
The present work describes, for the first time, a 
molecular clone of HIV-I with attenuated 
cytopathicity. Recent reports on noncytopathic 
HIV-II isolates [6,7] implied a correlation with the 
generally mild course of immunodeficiency in 
West African patients infected with this virus [8]. 
Our low-cytopathic HIV-I/NlT-E clone originated 
from a patient with lymphadenopathy [151, who 
remains relatively healthy. At the same time, this 
individual also carries highly cytopathic variants of 
HIV-I which are closely related to the NlT-E virus. 
It is impossible to conclude from the present data 
how those diverse variants may have evolved. 
However, comparative analysis of the cytopathic 
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and noncytopathic NIT viral clones may help to 
reveal the molecular basis for HIV-I cytopathicity. 
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